Announcements Trials
Browse Landscape

Status

No longer available 3Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 454Observational 20Expanded_access 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

elotuzumab 4Bortezomib 4Lenalidomide 3Dexamethasone 3talquetamab 2selinexor 2pomalidomide 2carfilzomib 2Panobinostat 2venetoclax 1ulocuplumab 1plerixafor 1idecabtagene vicleucel 1fludarabine phosphate 1daratumumab 1ceritinib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Melphalan 1Cytarabine 1Crizotinib 1Cord Blood Stem Cell Transplantation 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × Bortezomib × Plasma cell × Clear all
NCT02666209 2017-08-28

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer Institute

No longer available
Plasma cell

Multiple Myeloma

NCT00799539 2015-12-02

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Janssen-Ortho Inc., Canada

No longer available
Plasma cell

Multiple Myeloma

NCT01250808 2010-12-01

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Peking University

Available
Plasma cell

Multiple Myeloma

NCT00063791 2007-02-14

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Millennium Pharmaceuticals, Inc.

No longer available
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡